128 related articles for article (PubMed ID: 38419809)
1. Using Bayesian hierarchical modeling for performance evaluation of clinical trial accrual for a cancer center.
Shi X; Mudaranthakam DP; Wick JA; Streeter D; Thompson JA; Streeter NR; Lin TL; Hines J; Mayo MS; Gajewski BJ
Contemp Clin Trials Commun; 2024 Apr; 38():101281. PubMed ID: 38419809
[TBL] [Abstract][Full Text] [Related]
2. Accrual Prediction Program: A web-based clinical trials tool for monitoring and predicting accrual for early-phase cancer studies.
Liu J; Wick JA; Mudaranthakam DP; Jiang Y; Mayo MS; Gajewski BJ
Clin Trials; 2019 Dec; 16(6):657-664. PubMed ID: 31451012
[TBL] [Abstract][Full Text] [Related]
3. Bayesian accrual modeling and prediction in multicenter clinical trials with varying center activation times.
Liu J; Wick J; Jiang Y; Mayo M; Gajewski B
Pharm Stat; 2020 Sep; 19(5):692-709. PubMed ID: 32319194
[TBL] [Abstract][Full Text] [Related]
4. Stochastic modeling and prediction for accrual in clinical trials.
Zhang X; Long Q
Stat Med; 2010 Mar; 29(6):649-58. PubMed ID: 20082363
[TBL] [Abstract][Full Text] [Related]
5. A Curated Cancer Clinical Outcomes Database (C3OD) for accelerating patient recruitment in cancer clinical trials.
Mudaranthakam DP; Thompson J; Hu J; Pei D; Chintala SR; Park M; Fridley BL; Gajewski B; Koestler DC; Mayo MS
JAMIA Open; 2018 Oct; 1(2):166-171. PubMed ID: 30474074
[TBL] [Abstract][Full Text] [Related]
6. Modeling and validating Bayesian accrual models on clinical data and simulations using adaptive priors.
Jiang Y; Simon S; Mayo MS; Gajewski BJ
Stat Med; 2015 Feb; 34(4):613-29. PubMed ID: 25376910
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Development and Validation of a Clinical Trial Accrual Predictive Regression Model at a Single NCI-Designated Comprehensive Cancer Center.
Tate WR; Cranmer LD
J Natl Compr Canc Netw; 2016 May; 14(5):561-9. PubMed ID: 27160234
[TBL] [Abstract][Full Text] [Related]
9. Developing a model to predict accrual to cancer clinical trials: Data from an NCI designated cancer center.
Iruku P; Goros M; Gelfond J; Chang J; Padalecki S; Mesa R; Kaklamani VG
Contemp Clin Trials Commun; 2019 Sep; 15():100421. PubMed ID: 31372575
[TBL] [Abstract][Full Text] [Related]
10. Joint monitoring and prediction of accrual and event times in clinical trials.
Zhang X; Long Q
Biom J; 2012 Nov; 54(6):735-49. PubMed ID: 22907686
[TBL] [Abstract][Full Text] [Related]
11. Center-Specific Modeling Predicts Cancer Trial Accrual More Accurately Than Investigators and Random Effects Modeling at 16 Cancer Centers.
Tate WR; Abraham I; Cranmer LD
JCO Clin Cancer Inform; 2019 Jun; 3():1-12. PubMed ID: 31173517
[TBL] [Abstract][Full Text] [Related]
12. Bayesian modeling and prediction of accrual in multi-regional clinical trials.
Deng Y; Zhang X; Long Q
Stat Methods Med Res; 2017 Apr; 26(2):752-765. PubMed ID: 25367100
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
14. Creating and Implementing a Principal Investigator Tool Kit for Enhancing Accrual to Late Phase Clinical Trials: Development and Usability Study.
Higgins KA; Thomas A; Soto N; Paulus R; George TJ; Julian TB; Hartson Stine S; Markham MJ; Werner-Wasik M
JMIR Cancer; 2022 Aug; 8(3):e38514. PubMed ID: 36006678
[TBL] [Abstract][Full Text] [Related]
15. Optimizing Retrieval of Biospecimens Using the Curated Cancer Clinical Outcomes Database (C3OD).
Mudaranthakam DP; Shergina E; Park M; Thompson J; Streeter D; Hu J; Wick J; Gajewski B; Koestler DC; Godwin AK; Jensen RA; Mayo MS
Cancer Inform; 2019; 18():1176935119886831. PubMed ID: 31798300
[TBL] [Abstract][Full Text] [Related]
16. Predicting accrual in clinical trials with Bayesian posterior predictive distributions.
Gajewski BJ; Simon SD; Carlson SE
Stat Med; 2008 Jun; 27(13):2328-40. PubMed ID: 17979152
[TBL] [Abstract][Full Text] [Related]
17. Modeling and prediction of subject accrual and event times in clinical trials: a systematic review.
Zhang X; Long Q
Clin Trials; 2012 Dec; 9(6):681-8. PubMed ID: 22674642
[TBL] [Abstract][Full Text] [Related]
18. Accrual monitoring in cardiovascular trials.
Baldi I; Gregori D; Desideri A; Berchialla P
Open Heart; 2017; 4(2):e000720. PubMed ID: 29344371
[TBL] [Abstract][Full Text] [Related]
19. Accrual to the Breast Cancer Prevention Trial by participating Community Clinical Oncology Programs: a panel data analysis.
Klabunde CN; Kaluzny AD
Breast Cancer Res Treat; 1995 Jul; 35(1):43-50. PubMed ID: 7612903
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the impact of delayed study startup on accrual in cancer studies.
Ratnayake I; Do AT; Gajewski D; Pepper S; Ige O; Streeter N; Lin TL; McGuirk M; Gajewski B; Mudaranthakam DP
Res Sq; 2024 Apr; ():. PubMed ID: 38699379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
